EUCAST expert rules in antimicrobial susceptibility testing |
| |
| Authors: | R. Leclercq R. Cantón D.F.J. Brown C.G. Giske P. Heisig A.P. MacGowan J.W. Mouton P. Nordmann A.C. Rodloff G.M. Rossolini C.-J. Soussy M. Steinbakk T.G. Winstanley G. Kahlmeter |
| |
| Affiliation: | 1. Laboratoire de Microbiologie, CHU Côte de Nacre, Caen, France;2. EUCAST Subcommittee on Expert Rules;3. Servicio de Microbiología and CIBER en Epidemiología y Salud Pública (CIBERESP), Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain;4. EUCAST Steering Committee;5. Clinical Microbiology, MTC-Karolinska Institutet, Karolinska University Hospital, Solna, Sweden;6. Department of Pharmacy, Biology & Microbiology, University of Hamburg, Hamburg, Germany;7. Department of Medical Microbiology, Southmead Hospital, Bristol, UK;8. Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherland;9. Service de Bactériologie-Virologie, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France;10. Institut fur Medizinische Mikrobiologie der Universitat Leipzig, Leipzig, Germany;11. Dipartimento di Biotecnologie, Sezione di Microbiologia, Siena, Italy;12. Hôpital Henri Mondor, Service de Bactériologie, Creteil, France;13. Department of Bacteriology and Immunology, Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway;14. Department of Microbiology, Royal Hallamshire Hospital, Sheffield, UK;15. Clinical Microbiology, Central Hospital, Växjö, Sweden |
| |
| Abstract: | EUCAST expert rules have been developed to assist clinical microbiologists and describe actions to be taken in response to specific antimicrobial susceptibility test results. They include recommendations on reporting, such as inferring susceptibility to other agents from results with one, suppression of results that may be inappropriate, and editing of results from susceptible to intermediate or resistant or from intermediate to resistant on the basis of an inferred resistance mechanism. They are based on current clinical and/or microbiological evidence. EUCAST expert rules also include intrinsic resistance phenotypes and exceptional resistance phenotypes, which have not yet been reported or are very rare. The applicability of EUCAST expert rules depends on the MIC breakpoints used to define the rules. Setting appropriate clinical breakpoints, based on treating patients and not on the detection of resistance mechanisms, may lead to modification of some expert rules in the future. |
| |
| Keywords: | Antimicrobial susceptibility testing breakpoints EUCAST expert rules interpretive reading |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
